The FH Foundation is pleased to announce its collaboration with Express Scripts, a leading pharmacy benefit manager, to improve pharmacy coverage for patients with familial hypercholesterolemia.

"The FH Foundation applauds Express Scripts for its leadership, working with the FH Foundation to ensure that high-risk FH patients, for whom these novel therapies were approved, will have access to the care their healthcare provider has recommended," said Katherine Wilemon, Founder and CEO of the FH Foundation.

With these new, more inclusive criteria put into practice by Express Scripts last month, patients with an untreated LDL-cholesterol equal to or greater than 190 mg/dL whose LDL-cholesterol is still over 70 mg/dL on maximally tolerated statins plus Zetia will qualify for prior authorization for a prescribed PCSK9 inhibitor. 

Read the full press release here.